Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Arcutis Biotherapeutics Inc
(NQ:
ARQT
)
10.02
-0.16 (-1.57%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Oct 4, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Arcutis Biotherapeutics Inc
< Previous
1
2
3
4
5
6
7
Next >
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
May 15, 2024
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
May 15, 2024
We are covering the biggest pre-market stock movers for Wednesday with all of the latest happenings worth watching this morning!
Via
InvestorPlace
ARQT Stock Earnings: Arcutis Biotherapeutics Beats EPS, Beats Revenue for Q1 2024
May 14, 2024
ARQT stock results show that Arcutis Biotherapeutics beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.
Via
InvestorPlace
Arcutis Biotherapeutics Stock Climbs After Blockbuster Q1 Results
May 14, 2024
Arcutis Biotherapeutics reports its first-quarter financial results after the bell Tuesday.
Via
Benzinga
Evaluating Arcutis Biotherapeutics: Insights From 5 Financial Analysts
April 12, 2024
Via
Benzinga
Breaking Down Arcutis Biotherapeutics: 4 Analysts Share Their Views
February 28, 2024
Via
Benzinga
Earnings Scheduled For February 27, 2024
February 27, 2024
Companies Reporting Before The Bell • Gaotu Techedu (NYSE:GOTU) is expected to report quarterly loss at $0.07 per share on revenue of $100.49 million.
Via
Benzinga
Arcutis Biotherapeutics Inc. (NASDAQ: ARQT) Leading the Way in Friday Trading Based on Percentage Gain
February 09, 2024
Via
Investor Brand Network
12 Health Care Stocks Moving In Tuesday's After-Market Session
May 14, 2024
Via
Benzinga
Arcutis Announces First Quarter 2024 Financial Results and Provides Business Update
May 14, 2024
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Expert Panel Review Further Validates Use of ZORYVE® (roflumilast) Topical Foam, 0.3% for Treatment of Seborrheic Dermatitis Across Diverse Hair Types Published in Journal of Clinical and Aesthetic Dermatology
May 13, 2024
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Arcutis to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024
April 29, 2024
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Arcutis Appoints David Topper as Chief Financial Officer
April 10, 2024
Industry veteran with over 40 years of experience in finance, investment management, and investment banking
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
EQT, Genie Energy And Other Big Stocks Moving Lower On Monday
March 11, 2024
U.S. stocks were lower, with the Dow Jones index falling more than 150 points on Monday.
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Arcutis Promotes Todd Tucker to Chief Human Resources Officer
March 11, 2024
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Arcutis Presents Late-Breaking Data From INTEGUMENT-PED Phase 3 Trial of Roflumilast Cream 0.05% in Atopic Dermatitis in Children Ages 2 to 5 at the American Academy of Dermatology Annual Meeting
March 10, 2024
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
New Research Reveals Genomic Profile of Seborrheic Dermatitis and Answers Key Questions on Immune Response and Skin Barrier Dysfunction
March 09, 2024
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Arcutis Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares
March 04, 2024
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Arcutis Announces Acceptance of Late Breaking Abstract in Atopic Dermatitis Among Five New Topical Roflumilast Data Being Presented at the American Academy of Dermatology Annual Meeting
March 04, 2024
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Arcutis Announces Pricing of $150 Million Public Offering
February 28, 2024
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Arcutis Announces Proposed Public Offering
February 28, 2024
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Arcutis and Sato Announce Strategic Collaboration and Licensing Agreement for Topical Roflumilast in Japan
February 28, 2024
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Arcutis Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
February 27, 2024
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
10 Health Care Stocks Whale Activity In Today's Session
February 19, 2024
Via
Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
February 09, 2024
Via
Benzinga
MaxLinear Reports Q4 Results, Joins ING, Wolfspeed And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
February 01, 2024
U.S. stock futures were higher this morning, with the Nasdaq futures gaining around 90 points on Thursday.
Via
Benzinga
Journal of the American Academy of Dermatology Publishes ZORYVE (roflumilast) Foam, 0.3% Results for Seborrheic Dermatitis from Pivotal Phase 3 Trial
January 29, 2024
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Verizon Posts Upbeat Earnings, Joins RTX, Procter & Gamble And Other Big Stocks Moving Higher On Tuesday
January 23, 2024
U.S. stocks traded mixed, with the Dow Jones index falling around 70 points on Tuesday.
Via
Benzinga
Topics
Stocks
Exposures
US Equities
ZORYVE® (roflumilast) Topical Foam, 0.3%, for the Treatment of Seborrheic Dermatitis Launches in the United States
January 22, 2024
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
iRobot, AST SpaceMobile And Other Big Stocks Moving Lower In Friday's Pre-Market Session
January 19, 2024
U.S. stock futures were higher this morning, with the Nasdaq futures gaining over 100 points on Friday.
Via
Benzinga
< Previous
1
2
3
4
5
6
7
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.